Netflix and Video Streaming Widen Lead over Subscription TV in Customer Satisfaction, According to the ACSI
Reading Time: 5 minutes
ANN ARBOR, Mich.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/ACSI?src=hash” target=”_blank”gt;#ACSIlt;/agt;–Video streaming expands its lead over subscription TV service in terms
of customer satisfaction, rising 1.3% to a score of 76 on the American
Customer Satisfaction Index’s (ACSI®) 100-point scale,
according to the ACSI
Telecommunications Report 2018-2019. Subscription TV service sits
stagnant at 62, tied with internet service providers (ISPs) for last
place among all industries tracked by the ACSI.
Among the five telecommunications industries covered in the
report—subscription TV, ISPs, fixed-line telephone service,
video-on-demand service, and video streaming service—only video
streaming stands out.
“Video streaming once again proves itself to be the best of the telecom
industries in customer satisfaction,” said David VanAmburg, Managing
Director at the ACSI. “Traditional telecom providers have tried to step
up their game, but they’re not providing original content the way video
streaming is, and in part they suffer guilt by association—if customers
aren’t satisfied overall with Comcast, they’re probably going to ding
Comcast’s on-demand service too.”
Netflix takes the crown among video streaming services
Video streaming services are the top performers for customer
satisfaction among the five telecom industries. Competition is likely to
spur further improvement, with both Disney and Apple expected to release
inexpensive streaming services later this year.
Netflix gains 1% to secure first place at 79—and number one across all
five telecom categories—after sharing the lead with Sony’s PlayStation
Vue and Amazon Twitch last year. As its membership growth continues at a
record pace, ACSI data show Netflix ranks at the top for original
content among all streaming services.
Sony’s PlayStation Vue is steady in second place at 78, followed by
Microsoft Store at 77. Hulu steps up 1% to match Amazon Prime Video (up
1%) and Apple iTunes (down 1%) at 76.
The rest of the category falls below the industry average. Five services
cluster at 75: CBS All Access (up 1%), Google Play (unchanged), Amazon’s
gaming platform Twitch (down 4%), Walmart’s Vudu (unchanged), and
Google’s YouTube (down 1%). DISH Network’s Sling TV is the most improved
(up 4%), meeting HBO (up 3%) at 74. Starz matches the combined score of
smaller platforms at 72, while Showtime follows close behind, growing 1%
to 71.
AT&T’s DIRECTV Now falls 1% to 69, ahead of only Sony Crackle, which
remains unchanged at 68.
Subscription TV stagnates
For the past six years, customer satisfaction with subscription TV has
languished in the mid-to-low 60s, and in 2018, subscription sales
declined 3% to $103.4 billion.
AT&T’s U-verse TV holds the lead for subscription TV despite a 1% slip
to 69, followed by Verizon’s Fios at 68 and DISH Network at 67 (both
unchanged). AT&T’s satellite TV service, DIRECTV, gains 3% to an ACSI
score of 66, but this may be the result of shedding dissatisfied
subscribers, leaving only the most loyal customers.
Altice’s Optimum retreats 2% to 61, falling behind the industry average.
Charter’s Spectrum is among the few gainers in the industry, improving
2% to 59 to tie with Cox Communications, which slips 2%.
Frontier Communications ticks up 2% to match Comcast’s Xfinity, which
sits unchanged at 57. Mediacom follows closely with a 2% increase to 56.
Altice’s Suddenlink tumbles 5% to the bottom of the category at 55.
These companies are among the lowest-scoring firms tracked by the ACSI.
Verizon’s Fios holds its lead as AT&T Internet advances among ISPs
Unchanged at a score of 62, ISPs remain at the bottom of the ACSI
rankings. While many providers post gains this year, service is largely
considered to be slow and unreliable, and competition is limited in many
areas. Most ISPs are still falling short of providing good service at an
affordable price.
Verizon’s Fios is stable at the top of the category with an ACSI score
of 70, but AT&T Internet is closing in with a 1% uptick to 69.
Altice’s Optimum retreats 2% to 63 but remains the leader among coaxial
providers. Meanwhile, Comcast’s Xfinity inches closer to the industry
average, up 2% to 61. Cox Communications climbs 2% to 60, tying Altice’s
Suddenlink, which falls 2%. Charter’s Spectrum also dips 2% and
CenturyLink grows 2% to meet at 59.
The lowest-scoring ISPs all make gains. Mediacom improves the most, up
6% to 56, just behind Windstream, which rises 2% to 57. Frontier
Communications gains 2% but sits at the bottom of the industry at 55. As
in the subscription TV industry, firms scoring lowest here are also some
of the worst performers among the 400+ companies in the ACSI.
AT&T’s U-verse TV, other video-on-demand services struggle against
streaming
Customer satisfaction with video-on-demand service slips 1.5% to an ACSI
score of 67 as viewers continue to turn toward more satisfying streaming
services like Netflix and Hulu. Despite the threat of online
competition, the largest cable and satellite companies have done little
to spur improvement.
AT&T’s U-verse TV service held the lead a year ago, but now falls 3% to
share the top spot with Verizon’s Fios (unchanged) at a score of 72.
Satellite provider DISH Network drops 3% to 71 but remains just ahead of
DIRECTV, unchanged at 70.
Frontier Communications debuts in the category with a score of 67, in
line with the industry average. Three decliners meet at 66: Cox
Communications (down 1%), Altice’s Optimum (down 3%), and Comcast’s
Xfinity (down 1%). Charter’s Spectrum remains unchanged at the bottom of
the category with a 64.
Vonage stands apart for loyal customers of fixed-line telephone
service
As more than half of all U.S. households forgo landlines in favor of
wireless service, only the most loyal customers remain. Perhaps that’s
why overall customer satisfaction with fixed-line telephone service
climbs 1.4% to an ACSI score of 71.
Individual company performance, however, varies. Vonage steps up 1% to
77. As a VoIP provider, Vonage doesn’t need to maintain an
infrastructure, so it can focus resources on customer service.
Companies that provide both cable and internet service in addition to
landline telephone do not perform as well. Verizon Communications gains
1% to 73, followed by AT&T, unchanged at 72. Altice’s Optimum is static
at 69, followed by Cox Communications, Charter’s Spectrum, and Comcast’s
Xfinity—all posting modest gains to 67. Windstream is stable at 64.
The only two decliners are CenturyLink, which dips 2% to 65, and
Altice’s Suddenlink, which plummets 14% to 61. According to its
customers, Suddenlink’s service is the least reliable among fixed-line
providers in terms of service interruptions and outages. Frontier
Communications also comes in at 61, despite being the most improved with
a gain of 7%.
The ACSI Telecommunications Report 2018-2019 on subscription TV,
ISPs, fixed-line telephone service, video-on-demand service, and video
streaming service is based on interviews with 38,681 customers, chosen
at random and contacted via email between April 5, 2018, and March 27,
2019. Download the full Telecommunications
Report.
Stay tuned! On June 4, we will reveal the ACSI scores for wireless phone
service and cell phone manufacturers in a new report.
Follow the ACSI on LinkedIn
and Twitter at @theACSI.
No advertising or other promotional use can be made of the data and
information in this release without the express prior written consent of
ACSI LLC.
About ACSI
The American
Customer Satisfaction Index (ACSI®) has been a
national economic indicator for 25 years. It measures and analyzes
customer satisfaction with more than 400 companies in 46 industries and
10 economic sectors, including various services of federal and local
government agencies. Reported on a scale of 0 to 100, ACSI scores are
based on data from interviews with roughly 300,000 customers annually.
For more information, visit www.theacsi.org.
ACSI and its logo are Registered Marks of the University of Michigan,
licensed worldwide exclusively to American Customer Satisfaction Index
LLC with the right to sublicense.
Contacts
Katie Johnston, 610-228-2248
[email protected]
Indivior
Indivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018).
- Primary and Secondary End Points of the Study were Not Met
- Indivior Does Not Currently Expect to Exercise AEF0117 Option
SLOUGH, United Kingdom and RICHMOND, Va., Sept. 4, 2024 /PRNewswire/ — Indivior PLC (Nasdaq/LSE: INDV) is today providing an update following Aelis Farma’s announcement of the results from its clinical Phase 2B trial with AEF01171, evaluating the efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD). The purpose of this trial was twofold: (1) to show that AEF0117 (0.1, 0.3, 1 mg once a day for 12 weeks) lowers cannabis use and (2) to determine the endpoints and optimal dosage of AEF0117 for use in future studies. In this phase 2B study, patients were treatment-seeking participants, 84% of whom had severe CUD.
The results of the study demonstrated that the primary endpoint, the proportion of participants who reduced their cannabis use to ≤1 day per week, as well as secondary endpoints measuring the proportion of participants reaching either complete abstinence or who used ≤2 day per week, were not met. Although these results are disappointing, they indicate that significant work remains to be done to understand subpopulations of patients with CUD, specifically those with severe CUD.
This clinical Phase 2B study is part of the strategic collaboration between Aelis Farma and Indivior, which includes an exclusive option for Indivior to license the global rights to AEF0117. Given the lack of separation from placebo on primary and secondary endpoints and before seeing further additional favorable clinical data, Indivior does not currently expect to exercise its option.
Important Cautionary Note Regarding Forward-Looking Statements
This news release contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding whether: we will be able to ultimately demonstrate the safety and efficacy of AEF0117, which is a prerequisite to filing any New Drug Application; we might ever exercise our option for AEF0117 and, if so, when; and other statements containing the words “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “forecast,” “strategy,” “target,” “guidance,” “outlook,” “potential,” “project,” “priority,” “may,” “will,” “should,” “would,” “could,” “can,” “outlook,” “guidance,” the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future.
Actual results may differ materially from those because they relate to future events. Various factors may cause differences between Indivior’s expectations and actual results, including, among others, the risks described in our most recent annual report on Form 20-F beginning on page 9 as filed with the U.S. SEC and in subsequent releases; legal and market restrictions that may limit how quickly we can repurchaser our shares; the substantial litigation and ongoing investigations to which we are or may become a party; our reliance on third parties to manufacture commercial supplies of most of our products, conduct our clinical trials and at times to collaborate on products in our pipeline; our ability to comply with legal and regulatory settlements, healthcare laws and regulations, requirements imposed by regulatory agencies and payment and reporting obligations under government pricing programs; risks related to the manufacture and distribution of our products, most of which contain controlled substances; market acceptance of our products as well as our ability to commercialize our products and compete with other market participants; competition; the uncertainties related to the development of new products, including through acquisitions, and the related regulatory approval process; our dependence on third-party payors for the reimbursement of our products and the increasing focus on pricing and competition in our industry; unintended side effects caused by the clinical study or commercial use of our products; our ability to successfully execute acquisitions, partnerships, joint ventures, dispositions or other strategic acquisitions; our ability to protect our intellectual property rights and the substantial cost of litigation or other proceedings related to intellectual property rights; the risks related to product liability claims or product recalls; the significant amount of laws and regulations that we are subject to, including due to the international nature of our business; macroeconomic trends and other global developments such as armed conflicts and pandemics; the terms of our debt instruments, changes in our credit ratings and our ability to service our indebtedness and other obligations as they come due; changes in applicable tax rate or tax rules, regulations or interpretations and our ability to realize our deferred tax assets; and volatility in our share price due to factors unrelated to our operating performance or that may result from the potential move of our primary listing to the U.S.
Forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.
This release is being made by Kathryn Hudson, Company Secretary Indivior PLC.
About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
References:
- National Library of Medicine (U.S.) (2022, April). Effect of AEF0117 on treatment-seeking patients with cannabis use disorder (CUD) (SICA2). Identifier
NCT05322941 https://www.clinicaltrials.gov/study/NCT05322941
Logo – https://mma.prnewswire.com/media/1814851/Indivior_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/indivior-provides-update-on-aelis-farmas-clinical-phase-2b-study-results-with-aef0117-in-participants-with-cannabis-use-disorder-302237355.html
HERZLIYA, Israel and CALGARY, Alberta, Aug. 29, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it has completed its previously announced non-brokered private placement offering of 5,025,725 units of the Company (the “Units”) at a price of C$0.22 per Unit for gross proceeds of C$1,105,659.50 (the “Offering”).
Each Unit is comprised of: (i) one (1) common share in the capital of the Company (each a “Common Share”); and (ii) one (1) common share purchase warrant (each a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Common Share at a price of C$0.32 for a period of four (4) years from the date of issuance.
Innocan intends to use the proceeds of the Offering for working capital and general corporate purposes.
The securities issued to Canadian subscribers in connection with the Offering are subject to a hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws.
Iris Bincovich, Chief Executive Officer of the Company, stated “we are very pleased with our successful offering. I would like to extend my sincere gratitude to our investors for their unwavering support. We see this as a strong vote of confidence by both existing and new investors which demonstrates investor support of our vision and strategic direction. These new funds will provide us with additional working capital to enable us to capitalize on new opportunities and allow us to advance strongly on our growth plans.”
The Company is also pleased to announce that it has granted an aggregate of 300,000 stock options (each an “Option“) to certain consultants of the Company pursuant to the Company’s stock option plan (the “Plan“). Each Option may be exercised for one (1) common share in the capital of the Company (each, a “Share“) at a price of $0.25 per Share. The Options expire on August 27, 2029.
All Options granted vest in accordance with the following vesting schedule: (i) 1/3rd of the Options vested immediately at grant; (ii) 1/3rd of the Options will vest on February 28, 2025; and (iii) 1/3rd will vest on August 27, 2025; all subject to the terms and conditions of the Plan.
About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/
Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
[email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Logo – https://mma.prnewswire.com/media/2046271/4883982/Innocan_Pharma_Corporation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-announces-closing-of-private-placement-and-grant-of-stock-options-302234455.html
Cannabis
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
Dublin, Aug. 29, 2024 (GLOBE NEWSWIRE) — The “Europe Medical Cannabis Oil Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2024-2032.” report has been added to ResearchAndMarkets.com’s offering.
The Europe Medical Cannabis Oil market is poised for significant growth, projected to escalate from US$ 0.91 billion in 2023 to US$ 2.40 billion by 2032, advancing at a CAGR of 12.08%. In this comprehensive research report, the market is analyzed by:
- Derivatives;
- Source;
- Application;
- Route of Administration;
- End-user;
- Distribution Channel; and
- Country.
Market Highlights Identified in the Report
- Progressive legalization across Europe is creating a favorable regulatory environment, enhancing market expansion for medical cannabis oil products.
- Germany leads the market with a robust infrastructure and supportive regulations, while other countries like the UK, Italy, and Spain show significant growth potential based on evolving regulatory landscapes and market dynamics.
- Key players such as Tilray, Aurora Cannabis Inc., and GW Pharmaceuticals dominate the market, emphasizing research, strategic partnerships, and innovation to maintain competitive edge amidst evolving industry dynamics.
The medical cannabis oil market has experienced substantial growth as legalization and acceptance of cannabis-based treatments expand globally. Cannabis oil, derived from the cannabis plant through extraction methods, contains cannabinoids such as THC and CBD, known for their therapeutic properties. Increasing recognition of cannabis oil’s potential in alleviating symptoms of various medical conditions, including chronic pain, epilepsy, and anxiety disorders, has driven its adoption in medical settings.
Governments in several countries are progressively legalizing medical cannabis, creating a conducive regulatory environment for market expansion. Additionally, growing consumer awareness about alternative and natural therapies has fueled the demand for cannabis oil products. The market is characterized by diverse product offerings, including full-spectrum and CBD-isolate oils, catering to different therapeutic needs and preferences.
Despite regulatory challenges and stigma associated with cannabis, the medical cannabis oil market continues to evolve, driven by ongoing research, favorable legislative changes, and shifting attitudes toward cannabis-based therapies in healthcare.
Regional Insights
Germany is likely to maintain its leadership position in the European medical cannabis oil market due to its established infrastructure, supportive regulations, and strong healthcare system. Germany legalized medical cannabis in 2017, giving the market a head start compared to many other European countries. This established infrastructure and experience position Germany as a leader in the field. As awareness and acceptance of medical cannabis increase, the number of patients seeking treatment in Germany is steadily rising. This fuels market growth and incentivizes further investment in research and development.
Germany’s regulatory framework for medical cannabis is considered relatively patient-friendly compared to some other European countries. This facilitates access for patients with qualifying conditions. The UK legalized medical cannabis in 2018 and is experiencing an increase in patient access programs. This, coupled with ongoing research, could lead to significant market growth. Italy legalized medical cannabis in 2006 but has faced challenges with availability. As regulations become more streamlined and patient access expands, the Italian market holds significant growth potential. Spain has a well-established medical cannabis industry with a focus on domestic production. As regulations evolve and export opportunities increase, the Spanish market could see a boost.
Competitive Landscape
The Medical Cannabis Oil market is characterized by a vigorous competitive landscape, with prominent entities like Tilray, Aurora Cannabis Inc., GW Pharmaceuticals, Almiral, Bedrocan, and others at the forefront, collectively accounting for approximately 41 % of the overall market share. This competitive milieu is fueled by their intensive efforts in research and development as well as strategic partnerships and collaborations, underscoring their commitment to solidifying market presence and diversifying their offerings.
The primary competitive factors include pricing, product caliber, and technological innovation. As the Medical Cannabis Oil industry continues to expand, the competitive fervor among these key players is anticipated to intensify. The impetus for ongoing innovation and alignment with evolving customer preferences and stringent regulations is high. The industry’s fluidity anticipates an uptick in novel innovations and strategic growth tactics from these leading corporations, which in turn propels the sector’s comprehensive growth and transformation.
Key Topics Covered
Chapter 1. Research Framework
Chapter 2. Research Methodology
Chapter 3. Executive Summary: Europe Medical Cannabis Oil Market
Chapter 4. Europe Medical Cannabis Oil Market Overview
Chapter 5. Europe Medical Cannabis Oil Market Analysis, by Derivatives
Chapter 6. Europe Medical Cannabis Oil Market Analysis, by Source
Chapter 7. Europe Medical Cannabis Oil Market Analysis, by Application
Chapter 8. Europe Medical Cannabis Oil Market Analysis, by Route of Administration
Chapter 9. Europe Medical Cannabis Oil Market Analysis, by End-user
Chapter 10. Europe Medical Cannabis Oil Market Analysis, by Distribution Channel
Chapter 11. Europe Medical Cannabis Oil Market Analysis, by Country
Chapter 12. The UK Medical Cannabis Oil Market Analysis
Chapter 13. Germany Medical Cannabis Oil Market Analysis
Chapter 14. The Netherlands Medical Cannabis Oil Market Analysis
Chapter 15. Italy Medical Cannabis Oil Market Analysis
Chapter 16. Spain Medical Cannabis Oil Market Analysis
Chapter 17. Poland Medical Cannabis Oil Market Analysis
Chapter 18. Rest of Europe Medical Cannabis Oil Market Analysis
Chapter 19. Company Profiles (Company Overview, Financial Matrix, Key Product Landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
A selection of companies mentioned in this report includes, but is not limited to:
- Aurora Cannabis Inc.
- Bedrocan
- Biocann
- BIOTA Biosciences LLC
- Cannamedical
- Mary Jane CBD
- Sanity Group GmbH
- Tilray
- Valcon Medical
For more information about this report visit https://www.researchandmarkets.com/r/dh7q46
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
-
Cannabis2 weeks agoSilly Nice Announces Launch of New 1G 510 Vape Cartridge and 2G All-In-One Vape in New York Dispensaries This September
-
Cannabis2 weeks agoCannabis Cultivation Market – Global Food Additives, Oils, Tinctures, Cannabis Indica, Cannabis Sativa Forecast 2024-2030
-
Cannabis1 week ago
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
-
Cannabis2 weeks ago
Global Hemp Based Food Market Size To Worth USD 4.87 Billion By 2033 | CAGR Of 13.12%
-
Innocan1 week agoInnocan Pharma Announces Closing of Private Placement and Grant of Stock Options
-
Indivior4 days agoIndivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
